A Phase 3 interventional study of Epoetin alfa in Prostate and Carcinoma, sponsored by Janssen-Ortho Inc., Canada. Completed. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-04-27.
Sponsored by Janssen-Ortho Inc., Canada (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study was to evaluate the effect of treatment with epoetin alfa (recombinant human erythropoietin) or placebo on anemia related quality-of-life and anemia in hormone-refractory (not responding to hormone therapy) prostate cancer patients.
Anemia is a common problem experienced by patients with malignancy. Although cancer treatment such as systemic chemotherapy is an obvious cause, many cancer patients are anemic at presentation. Estimates in prostate cancer patients suggest that nearly 40% present with hemoglobin levels less than 120 g/L. The most common clinical manifestation of anemia is fatigue, although vertigo, loss of appetite, poor concentration and dyspnea (shortness of breath) can also occur. Anemia often leads to impairment of physical capacity, lowers patients' subjective sense of well-being, and diminishes their overall quality-of-life (QoL). The use of recombinant erythropoietin for patients with chronic anemia of end stage renal disease, acquired immune deficiency syndrome, or anemia of chronic disease in the setting of malignancy (cancer) is well established to provide benefit in reducing transfusion requirements. There exists a number of published data on QoL in cancer patients. Abels et al. published in 1991 initial results of clinical reports that specifically reported on QoL outcomes. The study actually consisted of a series of three concurrent randomized, double blind, placebo controlled trials conducted on groups of patients with a variety of underlying malignancies. The three studies included 124 patients not previously treated with systemic therapy, 132 patients treated systemically with cisplatinum containing chemotherapy regimens and 157 patients treated with non-cisplatinum containing regimens respectively. All patients had pre-treatment hemoglobins of less than 105 g/L or hematocrits (percentage of red blood cells in blood) of less than 32%. In each trial, patients randomized to receive recombinant erythropoietin had significantly greater increases in hematocrit than placebo patients. QoL parameters (as measured on a visual analog scale) were significantly improved in patients receiving erythropoietin who demonstrated an increase in hematocrit throughout the three studies. Overall QoL improved significantly over baseline, although individual studies only demonstrated a trend towards improvement. Littlewood et al. published in 2001 the results of a double-blind, placebo controlled multi-center study of 375 cancer patients receiving non-platinum containing chemotherapy. A baseline hemoglobin of less than or equal to 105 g/L, or a drop of 20 g/L with chemotherapy was required for eligibility. Patients were randomized 1:2 to either placebo or epoetin alfa, for up to 4 weeks following chemotherapy. Active treatment demonstrated significant effectiveness in increasing hemoglobin levels and reducing transfusion requirements. Significant improvement in all primary cancer- and anemia-specific QoL domains favoured epoetin alfa. Although clinical evidence suggests benefit beyond reduced transfusion requirements, many studies looking at impact on QoL have been uncontrolled by design, with variable quality and collection of QoL data. Since they have also involved patients with a myriad of primary malignancies, and previous therapies, the translation of results to site and situation specific clinical practice has been difficult. As erythropoiesis is a complex process that depends on inhibiting or stimulating cytokines, which may be regulated differently among various neoplastic diseases (i.e. different tumour types), studies in more homogenous groups of patients were deemed necessary to evaluate impact on QoL. Prostate cancer is the most common serious cancer in men. Despite advances in screening and treatment, progression to the incurable metastatic phase of the disease remains common. Androgen ablation therapy using surgery or drugs remains the standard of treatment, but inevitably, androgen resistance develops. Hormone refractory prostate cancer represents a spectrum of disease ranging from asymptomatic patients with only biochemical evidence of androgen resistance to end-stage disease characterized by extensive bone metastases, pain, wasting, reduced QoL, and a median survival of less than one year. Treatment of hormone refractory prostate cancer does not prolong survival, but may improve symptoms and QoL. Anemia is common in this group of patients, with hemoglobin levels of less than 120 g/L often seen (in up to 40% patients). Patients are also genrally older, often have co-morbid conditions, and transfusions for palliation are frequently given. A randomized, placebo-controlled study evaluating an intervention with epoetin alfa that could significantly improve QoL was thus carried out in hormone refractory prostate cancer patients. It was deemed that such an intervention, if successful, could have the potential to change current clinical practice. Moreover, improved QoL, in response to increased Hb levels, could also lead to a reduction in hospital admissions and to fewer transfusions in this patient population.
Patients were to receive either 40,000 IU epoetin alfa weekly or matching placebo subcutaneously for 16 weeks.
736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.
This study's enrollment of 56 is above the median of 49 across 571 interventional studies indexed under Carcinoma.
Browse Carcinoma studies →Janssen-Ortho Inc., Canada is the lead sponsor of 22 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The primary outcome was change in Quality of Life (FACT-An Anemia scale) from baseline to 16 weeks.
QoL was measured at baseline, 4, 8, 12, 16 and 20 weeks (FACT-An Total and Cancer Linear Analogue Scale). Hb and Hematocrit levels were assessed at baseline, 4, 8, 12, 16 and 20 weeks. Transfusion requirements were recorded throughout the trial.
No study locations are listed for this record.
The record gives a start of Dec 2002 and a completion of Mar 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epoetin Alfa